In this week’s episode we’ll review results of a trial of venetoclax plus low-dose cytarabine in untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, learn how HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression, and assess new data demonstrating that aromatase is a novel neosubstrate of cereblon responsible for thrombocytopenia caused by immunomodulatory drugs.